Stockscreener 앱 받기
0.3531
1.38%
-0.0019
Cosmos Health Inc 주식(COSM)의 최신 뉴스
Cosmos Health (COSM) price target increased by 50.00% to 4.59 - MSN
COSM Stock Price, Quote & Chart | COSMOS HEALTH INC (NASDAQ:COSM) - ChartMill
Cosmos Health (COSM) Projects Significant Revenue Growth with Cu - GuruFocus
Cosmos Health projects Cur18 to generate $2.5M in U.S. revenue - Investing.com
Cosmos Health Projects Over $2.5 Million in Incremental Annual Revenue from Cur18 in the United States Within 12-18 Months - ACCESS Newswire
A turmeric supplement is central to Cosmos Health's $2.5M U.S. sales bet - Stock Titan
Cosmos Health Continues US Expansion with Q2 Launch of Cur18a Clinically Studied, Patented Curcumin Next-Gen Therapy Supplement Delivering 39× Higher Bioavailability and Designed to Support Joint Health - ACCESS Newswire
Cosmos Health (COSM) holder reports 4.14M shares, 8.15% stake in amendment - Stock Titan
Cosmos Health Accelerates U.S. Expansion: Liv18 Phase 1 Execution Complete; Production and Sales Commencing April 2026; Expected to Generate $5M+ in Annual Revenue at ~75% Gross Margins; Early U.S. Commercial Traction Observed Across Produ - Palestineherald.com
73.5M Cosmos Health shares registered for resale (NASDAQ: COSM) - Stock Titan
Cosmos Health (COSM) Year-Ahead Outlook | Q4 2025: Below ExpectationsAcquisition - Xã Vĩnh Công
Is Cosmos Health (COSM) stock still a good play today | Q4 2025: Profit DisappointsReal-time Trade Ideas - Cổng thông tin điện tử tỉnh Lào Cai
Cosmos Health (COSM) Stock: Consolidation Phase Insight (Smart Money Flows) 2026-04-22Quantitative Analysis - Cổng thông tin điện tử tỉnh Lào Cai
Cosmos Health Introduces the "18 Series" in the United StatesA Science-Driven Nutraceutical Platform Built on Patented Ingredients, Published Clinical Research, and Exact Clinical Dosing; Targeting a Portfolio of 18 Clinically Validated Products - Finviz
Cosmos Health Inc.: Cosmos Health Introduces the 18 Series in the United StatesA Science-Driven Nutraceutical Platform Built on Patented Ingredients, Published Clinical Research, and Exact Clinical Dosing; Targeting a Portfolio of 18 Clinically Valid - FinanzNachrichten.de
This supplement line only launches products at exact clinical-trial doses - Stock Titan
Cosmos Health to begin Liv18 liver supplement production in April By Investing.com - Investing.com Australia
COSM earnings show rapid revenue growth - MSN
Cosmos Health to begin Liv18 liver supplement production in April - Investing.com
A U.S.-made liver supplement is central to Cosmos Health's $5M push - Stock Titan
Cosmos Health (COSM) Unveils Innovative Curcumin Supplement for U.S. Market - GuruFocus
Cosmos Health expands AI integration across operations By Investing.com - Investing.com Australia
Cosmos Health plans Q2 U.S. launch of curcumin supplement By Investing.com - Investing.com Australia
Cosmos Health plans Q2 U.S. launch of curcumin supplement - Investing.com
A turmeric supplement with 39x absorption heads to the U.S. in Q2 - Stock Titan
Trending Industry Today: Cosmos Health Leads Gains In ETH-Holding Companies Stocks - Moomoo
Form 4Statement of changes in beneficial ownership of securities - ADVFN
Cosmos Health expands AI integration across operations - Investing.com
Cosmos Health Advances AI Investments to Enhance Efficiency, Reduce Costs, Improve Customer Experience and Drive Sales Growth; Certain Operating Expenses May Decrease by Up to 30% - ACCESS Newswire
Cosmos Health says AI could trim some costs 30% while speeding orders - Stock Titan
Record 2025 revenue and margin expansion at Cosmos Health (COSM) - Stock Titan
Cosmos Health Inc. 2025 Annual Report: Growth Strategy, Product Portfolio, and Global Healthcare Market Expansion - Minichart
Cosmos Health (COSM) Achieves Record Revenue and Significant Mar - GuruFocus
Cosmos 2025 10-K: $65.3M Revenue, $(0.63) EPS on net loss - TradingView
Cosmos Health Inc. Reports Earnings Results for the Full Year Ended December 31, 2025 - marketscreener.com
Cosmos Health (NASDAQ: COSM) expands pipeline, AI drug repurposing and equity funding - Stock Titan
3.05%
2.63%
자본화:
|
볼륨(24시간):